

Immune checkpoint inhibition with single fraction stereotactic radiosurgery does not increase risk of radiation necrosis

November 1 2023







Competing risks analysis of any grade radiation necrosis. Cumulative incidence plots with death as a competing risk for the development of any grade RN. Figure 1A: Plot of all 395 patients, where the x-axis is the time in months since SRS and the y-axis is the incidence of any grade RN. The 1- and 2-year rates of any grade RN were 4.8% (95% CI 2.9%-7.3%) and 9.3% (95% CI 6.4%-13%), respectively. Figure 1B: Plot of all patients stratified by receipt of concurrent (blue) and non-concurrent (red) SRS and ICI administration. In the concurrent group, the 1- and 2-year rates of any grade RN were 3.8% (95% CI 1.4%-8.2%) and 8.7% (95% CI 4.1%-16%), respectively. In the non-concurrent group, the 1- and 2-year rates of any grade RN were 5.3% (95% CI 2.9%-8.8%) and 9.7% (95% CI 6.1%-14%), respectively. There were no significant differences in the development of any grade RN by ICI and SRS timing (p = 0.35) Abbreviations: CI: confidence interval; ICI: immune checkpoint inhibitors; RN: radiation necrosis; SRS: stereotactic radiosurgery. Credit: *Journal of Neuro-Oncology* (2023). DOI: 10.1007/s11060-023-04413-4

Miami Cancer Institute, part of Baptist Health South Florida, announced the publication of a multi-institutional retrospective cohort study about the impact of immune checkpoint inhibition (ICI) and single-fraction stereotactic radiosurgery (SRS) on radiation necrosis (RN) in patients with brain metastasis from non-small cell lung cancer.

The study, titled "Immune Checkpoint Inhibition and Single Fraction Stereotactic Radiosurgery in Brain Metastases from Non-Small Cell Lung Cancer: An International Multicenter Study of 395 Patients" is published in the *Journal of Neuro-Oncology*.

"One of the key findings of the study is that immune checkpoint inhibition, when administered together with <u>stereotactic radiosurgery</u>, does not increase the risk of radiation necrosis," said Manmeet S. Ahluwalia, M.D., MBA, FASCO, chief of medical oncology, chief



scientific officer, deputy director, and Fernandez Family Foundation Endowed Chair in Cancer Research at Miami Cancer Institute, and senior author of the study. "We did, however, find a relationship between the volume of the brain area that is targeted during radiation and radiation necrosis."

The study included 395 patients with 2,540 brain metastases who were treated with SRS and ICI across four countries with a median follow-up of 14.2 months. The median age of the study participants was 67 years. The median margin SRS dose was 19 Gy, but 36.5% of patients had a V12 Gy of larger or equal to 10 cm^3 .

On multivariable analysis, V12 Gy of larger or equal to 10 cm³ was a significant predictor of developing any grade RN and symptomatic RN (SRN). At one year, the cumulative incidence of any grade RN and SRN for all patients was 4.8% and 3.8%, respectively. For concurrent and non-concurrent groups, the cumulative incidence of any grade RN was 3.8% versus 5.3%, respectively; and for SRN was 3.8% vs. 3.6%, respectively.

"The risk of any grade radiation necrosis and symptomatic radiation necrosis following single fraction stereotactic radiosurgery and immune checkpoint inhibition for <u>non-small cell lung cancer</u> brain metastases increases as V12 Gy exceeds 10 cm³," added Ahluwalia.

"Concurrent immune checkpoint inhibition and stereotactic radiosurgery do not appear to increase this risk. Instead, radiosurgical planning techniques should aim to minimize V12 Gy. In addition, the study suggests that treatment with immune checkpoint inhibitors can continue when radiation necrosis occurs."

More information: Eric J. Lehrer et al, Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395



patients, *Journal of Neuro-Oncology* (2023). DOI: <u>10.1007/s11060-023-04413-4</u>

Provided by Baptist Health South Florida

Citation: Immune checkpoint inhibition with single fraction stereotactic radiosurgery does not increase risk of radiation necrosis (2023, November 1) retrieved 11 May 2024 from https://medicalxpress.com/news/2023.November 1) retrieved 11 May 2024 from https://medicalxpress.com/news/2023.November 1) retrieved 11 May 2024 from https://medicalxpress.com/news/2023-11-immune-checkpoint-inhibition-fraction-stereotactic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.